Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | TAF1 | P21675 | 1/20 | 0.32 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1497851 | 0.93 | CYP3A4 (0.37) | ALDH1A1NPSR1SMN1; SMN2USP2MEN1 | |
| SCHEMBL1497701 | 0.82 | ALDH1A1 (0.36) | ALDH1A1NPSR1SMN1; SMN2USP2MEN1 | |
| SCHEMBL1497877 | 0.80 | CNR1 (0.36) | ALDH1A1NPSR1SMN1; SMN2USP2MEN1 | |
| SCHEMBL1497720 | 0.79 | PDE10A (0.39) | ALDH1A1NPSR1SMN1; SMN2USP2MEN1 | |
| SCHEMBL7288748 | 0.78 | HTR3A (0.48) | ALDH1A1MEN1KMT2ACYP3A4HTR3A | |
| SCHEMBL1497787 | 0.77 | HTR3A (0.61) | ALDH1A1SMN1; SMN2KMT2AL3MBTL1CYP3A4 | |
| SCHEMBL1497721 | 0.77 | HTR3A (0.63) | CYP3A4HTR3A | |
| SCHEMBL1497847 | 0.74 | ALDH1A1 (0.37) | ALDH1A1NPSR1SMN1; SMN2USP2MEN1 | |
| SCHEMBL1497916 | 0.72 | CNR1 (0.36) | ALDH1A1NPSR1SMN1; SMN2USP2MEN1 | |
| SCHEMBL7306105 | 0.72 | CYP3A4 (0.41) | ALDH1A1NPSR1SMN1; SMN2USP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897614-B2 | Preventive agent/remedial agent for constipation predominant IBS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20100210679-A1 | PREVENTIVE AND THERAPEUTIC MEDICAMENT FOR GASTROESOPHAGEAL REFLUX DISEASE | YAMAZAKI SATOSHI | 2010-08-19 | — | — | US | disclosed |
| US-20100204267-A1 | Preventive and therapeutic medicament for gastroesophageal reflux disease | YAMAZAKI SATOSHI | 2010-08-12 | — | — | US | disclosed |
| US-20100168157-A1 | PREVENTIVE AND THERAPEUTIC MEDICAMENT FOR GASTROESOPHAGEAL REFLUX DISEASE | YAMAZAKI SATOSHI | 2010-07-01 | — | — | US | disclosed |
| EP-1829543-B1 | Preventive agent/remedial agent for constipation predominant IBS | MITSUBISHI TANABE PHARMA CORP (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20080293762-A1 | Preventive and Therapeutic medicament for gastroesophageal reflux disease | EDUSA PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| EP-1829543-A1 | Preventive agent/remedial agent for constipation predominant IBS | MITSUBISHI PHARMA CORPORATION (JP) | 2007-09-05 | — | — | EP | disclosed |
| EP-1256581-B1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR GASTRIC OR ESOPHAGEAL REGURGITATION | MITSUBISHI PHARMA CORP (JP) | 2007-03-28 | — | — | EP | disclosed |
| US-20070004770-A1 | Preventive agent/remedial agent for constipation predominant IBS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-04 | — | — | US | disclosed |
| US-20060281781-A1 | Preventive and therapeutic medicament for gastroesophageal reflux disease | EDUSA PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | disclosed |
| US-20050282852-A1 | Preventive and therapeutic medicament for gastroesophageal reflux disease | YAMAZAKI SATOSHI | 2005-12-22 | — | — | US | disclosed |
| US-6967207-B2 | Preventive or therapeutic agents for gastric or esophageal regurgitation | MITSUBISHI PHARMA CORPORATION (JP) | 2005-11-22 | — | — | US | disclosed |
| US-20040248927-A1 | Preventive agent/remedial agent for constipation predominant ibs | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-09 | — | — | US | disclosed |
| EP-1419772-A1 | PREVENTIVE AGENT/REMEDIAL AGENT FOR CONSTIPATION PREDOMINANT IBS | Mitsubishi Pharma Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-20030130304-A1 | Preventive or therapeutic agents for gastric or esophageal regurgitation | MITSUBISHI PHARMA CORPORATION (JP) | 2003-07-10 | — | — | US | disclosed |
| EP-1256581-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR GASTRIC OR ESOPHAGEAL REGURGITATION | Mitsubishi Pharma Corporation (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168157-A1 | PREVENTIVE AND THERAPEUTIC MEDICAMENT FOR GASTROESOPHAGEAL REFLUX DISEASE | HRH2, SLC10A2, GRPR | ALDH1A1 112/4885NPSR1 174/4885SMN1; SMN2 1953/4885 |
| US-20040248927-A1 | Preventive agent/remedial agent for constipation predominant ibs | BRS3, SLC10A2, FABP2 | ALDH1A1 1982/4885NPSR1 21/4885SMN1; SMN2 1351/4885 |
| US-20070004770-A1 | Preventive agent/remedial agent for constipation predominant IBS | SLC10A2, FABP2, SI | ALDH1A1 804/4885NPSR1 10/4885SMN1; SMN2 1066/4885 |
| US-20050282852-A1 | Preventive and therapeutic medicament for gastroesophageal reflux disease | HRH2, SLC10A2, GRPR | ALDH1A1 112/4885NPSR1 174/4885SMN1; SMN2 1953/4885 |
| US-20100210679-A1 | PREVENTIVE AND THERAPEUTIC MEDICAMENT FOR GASTROESOPHAGEAL REFLUX DISEASE | HRH2, SLC10A2, GRPR | ALDH1A1 112/4885NPSR1 174/4885SMN1; SMN2 1953/4885 |
| US-20100204267-A1 | Preventive and therapeutic medicament for gastroesophageal reflux disease | HRH2, SLC10A2, GRPR | ALDH1A1 112/4885NPSR1 174/4885SMN1; SMN2 1953/4885 |
| US-20080293762-A1 | Preventive and Therapeutic medicament for gastroesophageal reflux disease | HRH2, SLC10A2, GRPR | ALDH1A1 112/4885NPSR1 174/4885SMN1; SMN2 1953/4885 |
| US-20060281781-A1 | Preventive and therapeutic medicament for gastroesophageal reflux disease | HRH2, SLC10A2, GRPR | ALDH1A1 112/4885NPSR1 174/4885SMN1; SMN2 1953/4885 |
| US-20030130304-A1 | Preventive or therapeutic agents for gastric or esophageal regurgitation | HRH2, SLC10A2, ABCB11 | ALDH1A1 401/4885NPSR1 564/4885SMN1; SMN2 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.